



Section 7: Providing HCV testing and treatment to people who inject drugs

Dr. Niklas Luhmann (Médecins du Monde)
*Training “Hepatitis C and HR for PWUD”,
9th-13th May 2016, Hanoi, Vietnam*

MÉDECINS D
LÅKARE I VÅ
KTERS VAN D
VÄRLDEN ME
生组织 DOCTO



OF THE WORLD منظمة أطباء العالم LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΪ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS
S 世界医生组织 MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΪ ΤΟΥ ΚΟΣΜΟΥ DO
ÉDICOS DEL MUNDO 世界の医家団 ARZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÅKARE I VÅ
KOSMΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医家団 ARZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医
家 LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΪ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医家団 ARZ

Learning objective of the session:


- » Reflect on the arguments usually used to refuse PWID access to HCV testing and treatment
- » Understand key elements related to HCV testing and treatment for PWID

MÉDECINS D
LÅKARE I VÅ
KTERS VAN D
VÄRLDEN ME
生組織 DOCTO



OF THE WORLD منظمة أطباء العالم LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS
S 世界医生组织 MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DO
ÉDICOS DEL MUNDO 世界の医師団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÅKARE I VÅ
KOSMΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医師団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医
生 団 LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医師団 ÄRZ

Context



» 10 out of 16 million People Who Inject Drugs (PWID) have HCV antibodies**



Context

- » PWID-HCV+: 26% live in East/South-East Asia and 23.5% in Eastern Europe (Nelson, Lancet, 2011)
- » Very high HCV co-infection rates among HIV infected PWID (Platt L et al. Lancet infectious Disease 2016)
 - The midpoint HCV co-infection prevalence in HIV+ PWID in 123 studies of PWID of 82.4% (IQR 55.2–84.5)
- » Uptake to treatment :
 - 2-4% of PWID in High Income Countries**
 - Nearly 0% in Low and Middle Income Countries
 - Although effective and acceptable models of care exist

MÉDECINS D
LÅKARE I VÅ
KTERS VAN D
VÄRLDEN ME
生组织 DOCTO



OF THE WORLD العالم منظمة LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS
S 世界医生组织 MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD العالم منظمة LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DO
ÉDICOS DEL MUNDO 世界の医家団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD العالم منظمة LÅKARE I VÅ
KOGJOU DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医家団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医
家 LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医家団 ÄRZ

Anti-HCV prevalence in PWIDs and general population

Country	PWID	General Population
Brazil	39,5-69,6%	1,4%
Estonia	90%	5%
Germany	75%	0,75%
India	92%	1,5%
Indonesia	60-98%	3,9%
Mauritius	95%	2,1%
New Zealand	70%	0,3%
Pakistan	89%	5,9%
Thailand	90%	2,2%
Ukraine	70-90%	4%
United States	50-80%	1,8%
Vietnam	31-97,2%	0,4-1,7%

* Nelson Lancet. 2011


MÉDECINS D
LÄKARE I VÄ
KTERS VAN D
VÄRLDEN ME
生組織 DOCTO



OF THE WORLD منظمة أطباء العالم LÄKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS
S 世界医生组织 MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÄKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DO
ÉDICOS DEL MUNDO 世界の医師団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÄKARE I VÄ
KOSMΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医師団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医
生组织 LÄKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医師団 ÄRZ

Anti-HCV prevalence in PWIDs and general population

80% OF NEW INFECTIONS OCCUR AMONG CURRENT PWID IN MANY COUNTRIES



PEOPLE LIVING WITH HCV INFECTION

MÉDECINS D
LÅKARE I VÅ
KTERS VAN D
VÄRLDEN ME
生组织 DOCTO



OF THE WORLD منظمة أطباء العالم LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS
S 世界医生组织 MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DO
ÉDICOS DEL MUNDO 世界の医家団 ARZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÅKARE I VÅ
KOSMΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医家団 ARZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医
家 LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医家団 ARZ


Liver mortality and morbidity

MÉDECINS D
LÅKARE I VÅ
KTERS VAN D
VÄRLDEN ME
生組織 DOCTO



OF THE WORLD منظمة أطباء العالم LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS
S 世界医生组织 MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DO
ÉDICOS DEL MUNDO 世界の医療団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÅKARE I VÅ
KOSJOU DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医療団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医
生组织 LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医療団 ÄRZ

CHASE cohort





Fibrosis stage among RNA + PWID in Tbilissi

- » 11 impossible evaluations with FS
- » 177 FS evaluations

Fibrosis level	Result (%; n)
F0/F1	55.4% (n=98)
F2	15.8% (n=28)
F3	10.73% (n=19)
F4	11.82% (n=21)

Cirrhosis:

- » in people less than 40 years of age: 3.3% (n=3)
- » in people 40 to 44 years of age: 13.3% (n=4)
- » In people 45 or more years old: 23.3% (n=14)



Fibrosis stage among RNA + PWID in Haiphong

- » 104 Study participants
- » mainly men (95.2%)
- » median **age of 35.8 years**
- » all under ART
- » with 94.2% rate of undetectable HIV-RNA and a median CD4 cell count of 504 (361–624) /mm³
- » 69.2% reported past injection drug use
- » 33% were still injecting drugs and 20.2% were receiving opiate substitution treatment
- » **Current or past excessive alcohol consumption was reported in 67.3% patients**
- » The prevalence of positive HBs antigen (HBsAg) was 12.6%



Fibrosis stage among RNA + PWID in Haiphong

- » 89.4% had a positive HCV RNA
- » Genotype distribution:
 - genotypes 1: 68.8%
 - genotype 6: 25.8%
 - GT 5: 5.4%
 - genotype 3b: 5.4%
- » 41.3% had fibrosis F2 or more including
- » 23.1% with extensive fibrosis (F3) and/or cirrhosis (F4).



Preliminary results after one month of intervention in Vietnam

- » **55 (53,7%) patients came back to take their results**
- » 36 patients have been vaccinated for HBV (in 49 patients positive HCV, who are support free prevention by HBV vaccine)
- » **12 (11,8%) patients showed levels of fibrosis equivalent to level F3 – F4, who were considered to be in need of urgent treatment**
- » Only 1 patient was successfully referred to HCV treatment.

MÉDECINS D
LÅKARE I VÅ
KTERS VAN D
VÄRLDEN ME
生组织 DOCTO



OF THE WORLD العالم منظمة LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS
S 世界医生组织 MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD العالم منظمة LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DO
ÉDICOS DEL MUNDO 世界の医家団 ARZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD العالم منظمة LÅKARE I VÅ
KOSJOU DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医家団 ARZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医
家 LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医家団 ARZ


Access to Harm Reduction

MÉDECINS D
LÅKARE I VÅ
KTERS VAN D
VÄRLDEN ME
生组织 DOCTO




OF THE WORLD منظمة أطباء العالم LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS
S 世界医生组织 MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DO
ÉDICOS DEL MUNDO 世界の医家団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÅKARE I VÅ
KOSJOU DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医家団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医
家 LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医家団 ÄRZ

Sub-optimal coverage of Harm Reduction services



Syringe and
needle
programs

OST





The reality of the response

- » **Knowledge from HIV field:** Very limited prevention and treatment access for PWID in general

Example East and South East Asia and Eastern Europe (Mathers B et al . 2010, Lancet):

- **Percentage of PWID accessing NSP:**

- **E/SE-Asia: 7% (6–9)**

- Needles and syringes distributed per IDU per year:

- **E/SE-Asia: 30 (7–68)**

- Number of OST recipients per 100 PWID:

- **E/SE-Asia 4 (2–8)**

- » **The right of PWID to HIV prevention, care and treatment has not been respected internationally and especially in LMICS.**



Obstacles to treatment for PWIDs in LMICs

National policies on HCV often omit to mention PWIDs

If not explicitly excluded!

	Georgia	Ukraine	Vietnam	Russia	Myanmar	Indonesia
Existence of a national policy plan for viral hepatitis or HCV?	Yes	Yes	Yes	Yes	No	Yes
Prevention strategies for PWID	No	No	Yes	No	-	Yes
Treatment inclusion of PWID	Yes	No	No	No	-	No

(Luhmann et al. IJDP 2015)



HCV treatment possibilities for PWIDs

Country	National guideline for the treatment of HCV infection	PWID included in the guideline	Active Drug Users	Reimbursement of antiviral drugs
Belarus	Yes	-	-	State budget Free treatment for persons < 18y
Bulgaria	Yes	Yes, supplement, 2013	No 6 months abstinence period	National Health Insurance Fund, All health insured
Czech Republic	Yes	Yes, separate guideline, 2008	Yes	National Health Insurance Fund All health insured
Hungary	Yes	Yes, incorporated, 1994	No Abstinence period not specified	Health Insurance Funds All health insured
Moldova	Yes	Yes, incorporated, 2008	Yes	Health Insurance Fund 300 pts planned per year
Poland	Yes	Yes	Yes	Health Insurance Funds All health insured
Russian Federation	Yes	HIV-HCV co-infected only, 2012	No 3-6 months abstinence period	Federal and local budgets Only for HIV-HCV pts
Romania	Yes	Not mentioned, but not prohibited	Yes	Health Insurance Fund All health insured
Slovak Republic	Yes	Yes	No Abstinence period not specified	Health Insurance Fund All health insured
Ukraine	Yes	No	No	State budget

MÉDECINS D
LÅKARE I VÅ
KTERS VAN D
VÄRLDEN ME
生组织 DOCTO



OF THE WORLD منظمة أطباء العالم LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΪ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS
S 世界医生组织 MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΪ ΤΟΥ ΚΟΣΜΟΥ DO
ÉDICOS DEL MUNDO 世界の医療団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÅKARE I VÅ
KOSJOU DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医療団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医
界 LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΪ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医療団 ÄRZ

Case study Georgia

MÉDECINS D
LÅKARE I VÅ
KTERS VAN D
VÄRLDEN ME
生组织 DOCTO



OF THE WORLD العالم منظمة أطباء LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΪ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS
S 世界医生组织 MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD العالم منظمة أطباء LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΪ ΤΟΥ ΚΟΣΜΟΥ DO
ÉDICOS DEL MUNDO 世界の医療団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD العالم منظمة أطباء LÅKARE I VÅ
KOSMΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医療団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医
生 LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΪ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医療団 ÄRZ

Prejudice 1


PWID are difficult to reach, treatment uptake in PWID is expected to be low

MÉDECINS D
LÅKARE I VÅ
KTERS VAN D
VÄRLDEN ME
生組織 DOCTO



OF THE WORLD العالم منظمة LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΪ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS
S 世界医生组织 MÉDECINS DU MONDE 世界の医療団 ARZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD العالم منظمة LÅKARE I VÄ
ÉDICOS DEL MUNDO 世界の医療団 ARZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD العالم منظمة LÅKARE I VÄ
KOSMΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医療団 ARZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医
生组织 LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΪ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医療団 ARZ

What we tried in Georgia



- Social assessment (peer worker)
- Referral to medical center for eligibility confirmation and pre-treatment assessment


Non invasive screening within HR organization

MÉDECINS D
LÅKARE I VÅ
KTERS VAN D
VÄRLDEN ME
生组织 DOCTO



OF THE WORLD العالم منظمة LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΪ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS
S 世界医生组织 MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD العالم منظمة LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΪ ΤΟΥ ΚΟΣΜΟΥ DO
ÉDICOS DEL MUNDO 世界の医療団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD العالم منظمة LÅKARE I VÄ
KOSMΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医療団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医
生组织 LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΪ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医療団 ÄRZ

What we tried in Georgia



Support during the diagnostic process

Escorting, mediation, tracking, help with paperwork

Done in a PWID friendly center!



What we tried in Georgia

		N	%
Sociodemographics			
Age (Mean 46.3; SD 7.4)	Less than 40	43	18.2%
	40 to 50	109	46.2%
	50+	84	35.5%
Sex	Men	234	99.2%
Education	Secondary	61	26.2%
	Higher	172	73.8%
Employment	Unemployed/disabled	151	64.8%
	Employed	82	35.2%
Living arrangements	Unstable	25	10.7%
	Hosted	133	57.1%
	Own home	75	32.2%
Drug use			
Age of first injection		Mean 18.5; sd 3.1	
Injecting drug use in the last month		112	48.1%
OST		58	24.9%

No HIV coinfection

		N	%
HCV and liver disease			
Liver fibrosis	F3	89	37.7%
	F3-F4	16	6.8%
	F4	117	49.6%
	F3 or more according to fib4	14	5.9%
Genotype	Genotype 1	40	17.0%
	Genotype 2	61	26.0%
	Genotype 3	124	52.8%
	Mixed genotype	10	4.3%
Risk factors of fibrosis	Heavy alcohol drinking (>7 drinks, >4 per weeks)	22	9.4%
	Cannabis	109	46.8%
	Obesity (157 data)	40	25.5%
	HBV (235 data)	11	4.7%
	Diabetes (217 data)	10	4.6%
Past treatment (231 data)		9	3.9%
Treatment	Sofosbuvir + Rbv + Peglnter 12 w	100	42.4%
	Sofosbuvir + Ribavirine 24 weeks	76	32.2%
	Sofosbuvir + Ribavirine 12 weeks	30	12.7%
	Sofosbuvir + Ribavirine 48 weeks	1	0.4%
	Sofosbuvir + Ribavirine 20 weeks	29	12.3%




What we achieved

- » Number of PWID screened at HR center: **554**
- » Number of PWID having started treatment (F3+): **239**

Uptake and pre-treatment cascade (In a 6 month period)

For 100 people eligible
to treatment seen at
the HR center



MÉDECINS D
LÅKARE I VÅ
KTERS VAN D
VÄRLDEN ME
生組織 DOCTO




OF THE WORLD منظمة أطباء العالم LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΪ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS
S 世界医生组织 MÉDECINS DU MONDE 世界の医家団 ARZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÅKARE I VÅ
ÉDICOS DEL MUNDO 世界の医家団 ARZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÅKARE I VÅ
KOSJOU DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医家団 ARZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医
家 LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΪ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医家団 ARZ

Conclusion: referral to treatment

80% of those ARN positive start a treatment are specific measures are taken*.

What is working**

- » Organize targeted case finding
- » Use one step screening and confirmation (point of care, DBS)
- » Integrate screening to harm reduction / OST services
- » Use non invasive liver staging
- » Implement peer support
- » Fight against discrimination and criminalization



* Hallinan Drug Alcohol Depend. 2007, Lindenburg Eur J Gastroenterol Hepatol. 2011, Grebely Eur J Gastroenterol Hepatol. 2010, Grebely Drug Alcohol Depend. 2010, Harris J Addict Med. 2010

** Grebely IJDP. 2015, Mravcik Patient preference and adherence. 2013

MÉDECINS D
LÅKARE I VÅ
KTERS VAN D
VÄRLDEN ME
生组织 DOCTO



OF THE WORLD منظمة أطباء العالم LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS
S 世界医生组织 MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DO
ÉDICOS DEL MUNDO 世界の医療団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÅKARE I VÅ
KOSMΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医療団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医
生 LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医療団 ÄRZ

Prejudice 2

Due to their instability and lack of adherence, PWID may have bad treatment outcomes

MÉDECINS D
LÅKARE I VÅ
KTERS VAN D
VÄRLDEN ME
生组织 DOCTO



OF THE WORLD منظمة أطباء العالم LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΑΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS
S 世界医生组织 MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΑΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DO
ÉDICOS DEL MUNDO 世界の医師団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÅKARE I VÅ
KOSMΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医師団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医
生组织 LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΑΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医師団 ÄRZ

What we tried in Georgia



Peer support intervention to enhanced retention in
treatment

Done in a PWID friendly center!



What we achieved

*Preliminary results on 171 patients expected to have completed treatment in end of _____
March 2016 (54 data for SVR12)*

Adherence

- » 2 early stop (severe AE)
= **98.8% completed treatment**
- » 89.6% didn't delay any medical appointment
- » 82.1% did not missed any dose

		No missing dose	p
Active drug use	Yes	86.4%	0.229
	No	78.9%	
OST	Yes	80.0%	0.695
	No	82.8%	
Peg Interferon	Yes	77.8%	0.104
	No	87.9%	

Response rate


- » 100% at EOT
- » **83.0% SVR12**

		SVR12	p
Genotype	1 (12)	83.3%	0.009
	2 (9)	66.7%	
	3 (27)	96.3%	
	Mixed (5)	40%	
Liver fibrosis	F3, F3-F4 (24)	91.7%	0.127
	F4 (29)	75.9%	
Adherence	Missed 1 dose or + (13)	61.5%	0.018
	Perfect intake (40)	90.0%	



HCV treatment is effective in PWID - PEG-IFN/RBV

55.5% (95% CI, 50.6%–60.3%)





Conclusion: treatment outcomes and adherence

Drug use at treatment initiation has limited impact on treatment completion, adherence and SVR*.

What is working

- » On-site multidisciplinary integrated care (OST, HIV, etc.)
- » With access to harm reduction and social support
- » Peer support to avoid lost to follow-up

MÉDECINS D
LÅKARE I VÅ
KTERS VAN D
VÄRLDEN ME
生组织 DOCTO



OF THE WORLD منظمة أطباء العالم LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS
S 世界医生组织 MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DO
ÉDICOS DEL MUNDO 世界の医師団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÅKARE I VÅ
KOSMΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医師団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医
生 LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医師団 ÄRZ

Prejudice 3

**Reinfection due to ongoing high-risk behaviors in PWID
negate the potential benefit of treatment**



What we are trying in Georgia

» During treatment:

- Peer-support within an HR organization
- Access to prevention
- Specific counselings on HCV reinfection


» Follow-up after treatment

- Individual conseling on HCV reinfection at HR center
- PCR testing at 6 and 12 months after SVR12



What we achieved

Preliminary results on 171 patients expected to have completed treatment in end March 2016





Conclusion: treatment outcomes and adherence

Drug use at treatment initiation has limited impact on treatment completion, adherence and SVR*.

What is working to reduce HCV transmission

Integrated prevention methods can lower the risk of HCV infection of 50-80%*.

- » HR intervention including NSP, OST
- » Regular HCV testing

• * Aspinall IJDP. 2014; Nolan Addiction. 2014; Tsui, JAMA Internal Medicine. 2014, White Medical Journal of Australia. 2014
** Cunningham Nature Reviews. 2015, Grady Clin Infect Dis. 2013



Summary case study

Typical situation of middle income country – with **not optimal conditions**:

- » Strong criminalization
- » No possibility to have an on-site treatment program
- » Still peg Interferon and Ribavirin
- » Limitation F3 +F4

But it was feasible and it works!



HCV treatment among PWID – main barriers

» System level

- exclusion of PWID in treatment guidelines and national plans
- treatment conducted in tertiary centers; not adapted care facilities for PWID
- lack of Harm Reduction platforms

» Provider level

- concerns about adherence issues
- concerns about reinfection
- concerns about side effects and drug-drug interactions during treatment
- reluctance to treat active drug users

» Criminalization of drug use

(Marieta Simonova, EASL 2016)
(Wolfe et al. IJDP 2015)



WHO 2016 HCV treatment guidelines

- » “When caring for PWID, the central tenets of **respect and non-discrimination** should be followed, and additional adherence and psychological support given as required.”
- » “Care should be given only with informed consent.”
- » “Acceptability of services is a vital component of health care, and **peer interventions may help with reducing injecting drug use and promoting safer injection practices.**”
- » “As a population with a high prevalence of HCV infection, **all PWID should be offered screening for HCV as an integral component of a comprehensive package of harm reduction interventions.**”
- » “Potential reinfection should not be an argument to withhold treatment from PWID.”

MÉDECINS D
LÅKARE I VÅ
KTERS VAN D
VÄRLDEN ME
生组织 DOCTO



OF THE WORLD منظمة أطباء العالم LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS
S 世界医生组织 MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DO
ÉDICOS DEL MUNDO 世界の医療団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医生组织 DOCTORS OF THE WORLD منظمة أطباء العالم LÅKARE I VÅ
KOSMΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医療団 ÄRZTE DER WELT दुनिया के डॉक्टर MÉDECINS DU MONDE 世界医
生组织 LÅKARE I VÄRLDEN MEDICI DEL MONDO ΓΙΔΤΡΟΙ ΤΟΥ ΚΟΣΜΟΥ DOKTERS VAN DE WERELD MÉDICOS DO MUNDO MÉDICOS DEL MUNDO 世界の医療団 ÄRZ



AGENCE FRANÇAISE
DE DÉVELOPPEMENT

This presentation was produced with the financial support of the French development agency (AFD – Agence Française de développement). The ideas and opinions it contains are those of Médecins du Monde and do not necessarily represent those of AFD.